Genelux Corporation

NasdaqCM GNLX

Genelux Corporation Dividends Paid for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.00

Genelux Corporation Dividends Paid is USD 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Dividends paid is cash paid to shareholders as a distribution of profits.

Genelux Corporation Dividends Paid for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
Genelux Corporation Dividends Paid for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.00.

Key data

Date	Dividends Paid	Capital Expenditure	Other Financing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: GNLX

Genelux Corporation

CEO	Mr. Thomas Zindrick J.D.
IPO Date	Jan. 26, 2023
Location	United States
Headquarters	2625 Townsgate Road
Employees	24
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Key trends

Past 5 years